Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  264.83
-0.18 (-0.07%)
AAPL  303.01
+0.76 (0.25%)
AMD  438.79
-8.79 (-1.96%)
BAC  50.98
-0.25 (-0.49%)
GOOG  384.83
-0.07 (-0.02%)
META  601.40
-3.66 (-0.60%)
MSFT  418.56
-2.50 (-0.59%)
NVDA  218.82
-4.65 (-2.08%)
ORCL  188.92
+0.76 (0.40%)
TSLA  417.21
-0.05 (-0.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.